- Home
- QLGN
as 07-25-2025 4:00pm EST
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | CALIFORNIA |
| Market Cap: | 4.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -9.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.73 - $13.50 | Next Earning Date: | 07-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Qualigen Therapeutics Inc. News
QLGN Breaking Stock News: Dive into QLGN Ticker-Specific Updates for Smart Investing
MT Newswires
2 months ago
Qualigen Therapeutics Receives Nasdaq Deficiency Notice
GlobeNewswire
2 months ago
Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q
GlobeNewswire
3 months ago
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
GlobeNewswire
4 months ago
Qualigen seeks to enter the $10 Billion CABG market with non-binding MOU to acquire Marizyme
GlobeNewswire
6 months ago
Qualigen to participate in next funding round for NanoSynex
MT Newswires
8 months ago
Qualigen Therapeutics Regains Compliance With Nasdaq's Minimum Bid Price, Equity Rules
GlobeNewswire
8 months ago
Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
GlobeNewswire
8 months ago
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Compare QLGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QLGN Qualigen Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.